Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 2063 results found since Jan 2013.

An Unusual Case of Arm Pain in a Young Soccer Player: Herpes Zoster in the Pediatric Athlete
Curr Sports Med Rep. 2022 Nov 1;21(11):386-390. doi: 10.1249/JSR.0000000000001005.ABSTRACTHerpes zoster (HZ), shingles, is caused by the varicella-zoster virus (VZV). HZ develops as a reactivation of latent VZV and is characterized by a painful, vesicular rash typically manifesting in a dermatomal distribution on the arms, trunk or face. HZ occurs in individuals who had primary VZV disease (chickenpox) as a child or in those who have received live, attenuated VZV vaccine. HZ is common in the elderly and the immunocompromised, with age being the single greatest risk factor. The incidence of HZ in children is 74/100,000 pers...
Source: Current Sports Medicine Reports - November 7, 2022 Category: Sports Medicine Authors: James MacDonald Joy Mosser-Goldfarb Cristina Tomatis Souverbielle Steven Cuff Source Type: research

Impact of COVID-19 pandemic on recommended vaccine uptake in a single-practice primary care COPD cohort in the UK
Conclusions: Uptake of recommended vaccines in COPD patients was high; seasonal influenza vaccine uptake showed a trend increase during the COVID-19 pandemic.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Singh, M., Singh, K. Tags: 01.03 - General practice and primary care Source Type: research

Utilization of Preventive Health Care in Adults and Children With Eczema
Conclusions Eczema in adults and children is associated with greater utilization of preventive health care and health maintenance, but not cancer screening.
Source: American Journal of Preventive Medicine - November 6, 2015 Category: Global & Universal Source Type: research

Pediatric vaccine ‐strain herpes zoster: a case series
ConclusionsWhile vaccination against VZV has overall reduced the incidence of both varicella and HZ in US children, given the widespread use of the VZV vaccine, awareness of the possibility of vaccine‐induced HZ remains an important consideration.
Source: Pediatric Dermatology - September 25, 2017 Category: Dermatology Authors: Sean Dreyer, Peera Hemarajata, Marcia Hogeling, Gregory P. Henderson Tags: ORIGINAL ARTICLE Source Type: research

Primary Care Screening and Comorbidity Management in Rheumatoid Arthritis in Ontario, Canada
ConclusionFor both RA and non‐RA patients, compliance with Canadian recommendations for preventive medical services and screening for comorbid conditions in primary care was less than optimal. This indicates key targets for improvement.
Source: Arthritis Care and Research - August 22, 2017 Category: Rheumatology Authors: Jessica Widdifield, Noah M. Ivers, Sasha Bernatsky, Liisa Jaakkimainen, Claire Bombardier, J. Carter Thorne, Vandana Ahluwalia, J. Michael Paterson, Jacqueline Young, Laura Wing, Karen Tu Tags: Original Article Source Type: research

Herpes Zoster Ophthalmicus.
Abstract Herpes zoster is a commonly encountered disorder. It is estimated that there are approximately 1 million new cases of herpes zoster in the United States annually, with an incidence of 3.2 per 1000 person-years. Patients with HIV have the greatest risk of developing herpes zoster ophthalmicus compared with the general population. Other risk factors include advancing age, use of immunosuppressive medications, and primary infection in infancy or in utero. Vaccination against the virus is a primary prevention modality. Primary treatments include antivirals, analgesics, and anticonvulsants. Management may requ...
Source: Primary Care - September 1, 2015 Category: Primary Care Authors: Johnson JL, Amzat R, Martin N Tags: Prim Care Source Type: research

Impact of medical and/or pharmacy reimbursement on adult vaccination rates.
CONCLUSIONS:  Among members with commercial health insurance, HZV and PV rates were significantly higher among those whose insurance covered vaccinations under both medical and pharmacy benefits, compared with members whose insurance covered vaccines under the medical benefit only. Pharmacy-based vaccination coverage from commercial health insurance plans may help improve adult vaccination rates. PMID: 30020746 [PubMed - in process]
Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Deshpande G, Visaria J, Singer J, Johnson KD Tags: Am J Manag Care Source Type: research

Matthew ’s health care tidbits: The Stupidity Vaccine
Each week I’ve been adding a brief tidbits section to the THCB Reader, our weekly newsletter that summarizes the best of THCB that week (Sign up here!). Then I had the brainwave to add them to the blog. They’re short and usually not too sweet! –Matthew Holt For my health care tidbits this week, I think we need a new vaccine. We need one that prevents stupidity.Look I get that some people don’t think the flu vaccine is effective and don’t think the effects are too bad, so they don’t get one every year. Many people don’t get a vaccine for shingles. But as someone who had shingles long before the recommended ...
Source: The Health Care Blog - March 5, 2022 Category: Consumer Health News Authors: matthew holt Tags: Health Policy Matthew Holt vaccines Source Type: blogs

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Clinical and epidemiological aspects of herpes zoster disease in a primary care setting in Riyadh, Saudi Arabia: A retrospective cohort study
CONCLUSIONS: Zoster vaccination uptake was low. A national program for adult vaccination, including zoster vaccination, should be developed, and a guideline to direct primary health-care professionals in the management of HZ infections should be implemented.PMID:36618136 | PMC:PMC9810876 | DOI:10.4103/jfmpc.jfmpc_933_22
Source: Herpes - January 9, 2023 Category: Infectious Diseases Authors: Abdullah S Binsaeedu Abubakr O Bajaber Aiman G Muqrad Yaser A Alendijani Hamad A Alkhenizan Thamer A Alsulaiman Abdullah H Alkhenizan Source Type: research